降浊方改善血脂异常大鼠脂质谱的TMT蛋白质组学研究
该研究采用高脂饮食建立血脂异常大鼠模型,给予高剂量降浊方(9 g/d)和低剂量降浊方(4.5 g/d)治疗四周,通过血清血脂检测和油红O染色评估疗效,并利用TMT定量蛋白质组学技术分析肝脏组织差异表达蛋白。结果显示降浊方可显著改善血清血脂谱和肝脏脂肪沉积,鉴定出123个差异表达蛋白(65个上调、58个下调),涉及胆固醇代谢、PPAR信号通路和胆汁分泌等通路,APOB、APOE、CYP7A1和HMGCS1可能是关键靶点。
要点
- 降浊方高剂量9 g/d和低剂量4.5 g/d均可改善血脂异常大鼠血脂谱和肝脏脂肪沉积。
- TMT蛋白质组学鉴定出123个差异蛋白,富集于胆固醇代谢、PPAR信号通路和胆汁分泌。
- APOB、APOE、CYP7A1和HMGCS1可能是降浊方调脂的关键蛋白靶点。
核心结论
- 降浊方可通过参与胆固醇代谢、PPAR信号通路和胆汁分泌的多条途径有效改善血脂谱。
- 蛋白质组学结果表明降浊方可能是治疗血脂异常的有前景的药物。
研究设计与样本
- 采用Q-Orbitrap高分辨液相色谱质谱法鉴定降浊方中的天然成分。
- 大鼠通过高脂饮食四周建立血脂异常模型,随后分别给予高剂量降浊方(9 g/d)和低剂量降浊方(4.5 g/d)治疗四周。
- 治疗结束后进行血清血脂检测和油红O染色评估疗效,并采用TMT定量蛋白质组学技术分析肝脏组织蛋白。
主要发现
- 降浊方可显著改善血清血脂谱和肝脏脂肪沉积。
- 降浊方干预后共检测到123个差异表达蛋白,包括65个上调蛋白和58个下调蛋白。
- KEGG通路分析显示胆固醇代谢、PPAR信号通路和胆汁分泌是参与脂质代谢紊乱的主要通路。
- GO分析提示位于细胞、调节细胞过程及具有结合活性的蛋白有助于脂质降低。
- 蛋白质组学、Western blot和PCR联合分析提示APOB、APOE、CYP7A1和HMGCS1可能在降浊方降脂网络中起关键作用。
临床怎么用
- 降浊方临床用于治疗血脂异常,本研究为其调脂作用提供了蛋白质组学层面的机制证据。
- 降浊方可能通过调控APOB、APOE、CYP7A1和HMGCS1等蛋白发挥降脂作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Jiangzhuo Formula (JZF) is a traditional Chinese herbal prescription that is clinically applied to treat dyslipidemia. However, the mechanism underlying its efficacy remains unexplored. AIM OF THE STUDY: This study aims to elucidate the underlying mechanisms, explore potential pathways, and identify the key proteins of JZF for the treatment of dyslipidemia. METHODS: In this work, Q-Orbitrap high-resolution liquid chromatography mass spectrometry was used to identify the natural ingredients in JZF, rats with dyslipidemia were established via a high-fat diet for four weeks, then the dyslipidemia rats were treated with high-dose JZF (9 g/d) and low-dose JZF (4.5 g/d) for four weeks. After treatment, serum lipid detection and Oil-red-O staining were conducted to assess the efficacy of JZF in ameliorating dyslipidemia. Tandem mass tag (TMT) -based quantitative proteomics technology was then used to evaluate the roles and importance of proteins from the extracted hepatic tissue. The differentially expressed proteins were assessed by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, Gene Ontology (GO), and protein-protein interaction (PPI) networks. Western blot and PCR analysis were used to validate the potential targets regulated by JZF. RESULTS: JZF could significantly improve the blood lipid profiles of serum and fat deposits of the liver. A total of 123 differentially expressed proteins were detected after JZF intervention, comprising 65 up-regulated proteins and 58 down-regulated proteins. The KEGG pathway analysis revealed that cholesterol metabolism, the PPAR signaling pathway, and bile secretion were the principal pathways involved in the disordered lipid metabolism, while GO analysis suggested that proteins that are located in the cell, regulate cellular processes, and show binding activity contribute to reductions in lipids. The combination of proteomics, Western blot, and PCR suggested that Apolipoprotein B (APOB), Apolipoprotein E (APOE), cholesterol 7 alpha-hydroxylase A1 (CYP7A1), and Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1) might play critical roles in JZF's lipid-lowering network. CONCLUSION: JZF can effectively improve lipid profiles via multiple pathways involved in cholesterol metabolism, the PPAR signaling pathway, and bile secretion. Generally, the proteomics techniques used in this research show that JZF could be a promising drug for the treatment of dyslipidemia.
引用
- Pan L, Tian Y, Sun H, et al. TMT-based proteomics analysis reveals the efficacy of jiangzhuo formula in improving the lipid profiles of dyslipidemia rats. J Ethnopharmacol. 2020. PMID: 32931881. doi:10.1016/j.jep.2020.113390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。